{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T20:51:07Z","timestamp":1771879867135,"version":"3.50.1"},"reference-count":41,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["No. 2020YFC2009000"],"award-info":[{"award-number":["No. 2020YFC2009000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Renal anaemia is a common complication of chronic kidney disease (CKD). Roxadustat is the first\u2010in\u2010class oral hypoxia\u2010inducible factor prolyl hydroxylase inhibitor for the treatment of anaemia. In this systematic review, we aimed to investigate the efficacy and safety of roxadustat in the treatment of anaemia in CKD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PubMed, Cochrane Library, Embase, and <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link> databases were searched from their inception to February 2021 for randomised controlled trials (RCTs) that compared the efficacy and safety of roxadustat to those of an erythropoiesis\u2010stimulating agent (ESA) or a placebo in treating anaemia in CKD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Nine RCTs involving 2743 patients were found. The meta\u2010analysis showed that roxadustat increased haemoglobin (Hb) level by 0.91\u2009g\/dL (95% confidence interval [CI]: 0.47\u20131.34, <jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05), transferrin level by 0.50\u2009mg\/dL (95% CI: 0.34\u20130.65, <jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05), and total iron\u2010binding capacity by 50.64\u2009\u03bcg\/dL (95% CI: 36.21\u201365.07, <jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05) in CKD patients. Decreases in hepcidin (mean difference [MD]\u2009=\u2009\u221223.16, 95% CI: \u221237.12 to \u22129.19, <jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05) and ferritin (MD\u2009=\u2009\u201038.35, 95% CI: \u221267.41 to \u22129.29, <jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05) levels were also observed. There was no significant difference in the incidence of adverse events (AEs) (OR: 1.12, 95% CI: 0.95\u20131.32, <jats:italic>P<\/jats:italic>\u2009=\u2009.17) between the roxadustat and control groups; however, the incidence of serious AEs in the roxadustat group was significantly higher than that in the ESA group (OR: 1.33, 95% CI: 1.06\u20131.68, <jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Roxadustat can significantly improve renal anaemia in CKD patients by increasing Hb level and iron metabolism. However, attention must be paid to the risk of SAEs during treatment.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.15055","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T16:40:03Z","timestamp":1629823203000},"page":"919-932","source":"Crossref","is-referenced-by-count":32,"title":["Efficacy and safety of roxadustat for anaemia in dialysis\u2010dependent and non\u2010dialysis\u2010dependent chronic kidney disease patients: A systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0971-0343","authenticated-orcid":false,"given":"Li","family":"Zheng","sequence":"first","affiliation":[{"name":"Evidence\u2010Based Medicine Center, School of Basic Medical Sciences Lanzhou University  Lanzhou China"},{"name":"Department of Pharmacy China Aerospace Science &amp; Industry Corporation 731 Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0054-2454","authenticated-orcid":false,"given":"Jinhui","family":"Tian","sequence":"additional","affiliation":[{"name":"Evidence\u2010Based Medicine Center, School of Basic Medical Sciences Lanzhou University  Lanzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5887-4120","authenticated-orcid":false,"given":"Deping","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine Chinese Academy of Medical Sciences  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy China Aerospace Science &amp; Industry Corporation 731 Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyong","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy China Aerospace Science &amp; Industry Corporation 731 Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yatong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Beijing Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuming","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism and Nephropathy China Aerospace Science &amp; Industry Corporation 731 Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,9,30]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.02.035"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(96)90130-4"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.17.2038"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-016-0312-9"},{"key":"e_1_2_9_6_1","first-page":"195","article-title":"Erythropoietin stimulating agents in the management of anemia of chronic kidney disease","volume":"2","author":"Hayat A","year":"2008","journal-title":"Patient Prefer Adherence"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.2174\/09298673113206660270"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065485"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000450779"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.274"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014111139"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1908978"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.8b00274"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S175887"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01077-1"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901713"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813599"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv302"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.12.020"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfx011"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-00943-4"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019060623"},{"key":"e_1_2_9_26_1","unstructured":"NCT.A phase 3 randomized double\u2010blind placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis. Clinicaltrialsgov [http:\/\/clinicaltrialsgov]. 2020."},{"key":"e_1_2_9_27_1","unstructured":"NCT.A phase 3 randomized open\u2010label active\u2010controlled study to evaluate the efficacy and safety of roxadustat in the maintenance treatment of anemia in end stage renal disease patients on stable dialysis. Clinicaltrialsgov [http:\/\/clinicaltrialsgov]. 2020."},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn601"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015030241"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1159\/000454818"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200318181"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-019-00652-9"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104747"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.12.18"},{"key":"e_1_2_9_35_1","first-page":"gfaa110","article-title":"The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta\u2010analysis","volume":"14","author":"Zheng Q","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-020-02693-7"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.21037\/apm-21-456"},{"key":"e_1_2_9_38_1","unstructured":"ProvenzanoR FishbaneS WeiLJ et al. Pooled efficacy and cardiovascular safety results of roxadustat in the treatment of anemia in chronic kidney disease patients on and not on dialysis. American Society of Nephrology (ASN) Kidney Week; 2019."},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201902240R"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy014"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.07.019"},{"issue":"5","key":"e_1_2_9_42_1","first-page":"344","article-title":"Roxadustat: another drug that causes pulmonary hypertension? Report of first human case","volume":"129","author":"Cygulska K","year":"2019","journal-title":"Pol Arch Intern Med"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15055","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15055","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T14:30:39Z","timestamp":1692973839000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1111\/bcp.15055"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15055","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,30]]}}}